Tumoral Calcinosis as an Initial Complaint of Juvenile-Onset Amyopathic Dermatomyositis

Eun Jin Doh, Jungyoon Moon, Sue Shin, Soo Hyun Seo, Hyun Sun Park, Hyun-Sun Yoon, Soyun Cho

Departments of Dermatology and 1Laboratory Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea

Calcinosis is rarely observed in juvenile-onset amyopathic dermatomyositis in contrast to juvenile-onset dermatomyositis. A 6-year-old female presented with several 0.5 to 2 cm-sized painless grouped masses on both knees for 3 years. The patient also presented with multiple erythematous scaly patches and plaques on both elbows, knuckles, buttock, ankles and cheeks. Her mother had similar skin lesions which were erythematous scaly patches on the knuckles and elbows, since her childhood. When skin biopsy was performed from a left knee nodule, liquid chalky discharge was observed. The biopsy results were consistent with calcinosis cutis. Other biopsies from erythematous patch of the patient and erythematous patch of her mother showed vacuolization of basal cell layer with inflammatory cell infiltrations. Laboratory findings showed normal range of serum phosphorus (4.5 mg/dl), calcium (9.3 mg/dl), 1,25-dihydroxy-vitamin D (10.8 ng/ml) and parathyroid hormone levels (11 pg/ml). Both patient and her mother had no history of muscle weakness and showed normal levels of muscle-specific enzyme. Both patients were diagnosed with juvenile-onset amyopathic dermatomyositis based on histopathology and cutaneous manifestations with no evidence of muscle weakness and no serum muscle enzyme abnormalities. Tumoral calcium deposits observed in daughter was diagnosed as dystrophic calcinosis which can be rarely seen in juvenile-onset amyopathic dermatomyositis. The patient is being treated with oral acetazolamide (40 mg/kg/d) for calcinosis. (Ann Dermatol 28(3) 375 380, 2016)

-Keywords-
Adolescent, Amyopathic dermatomyositis, Calcinosis

INTRODUCTION

Calcinosis cutis is the deposition of insoluble calcium salts in the skin and subcutaneous tissue. Calcinosis cutis is divided into five subtypes: dystrophic calcification, metastatic calcification, idiopathic calcification, iatrogenic calcification, and calciphylaxis. Dystrophic calcification is the most common subtype of calcinosis cutis which is characterized by normal calcium and phosphate levels in serum. Dystrophic calcification appears as a result of local tissue damage and is most frequently observed in underlying autoimmune connective tissue disease (ACTD). Dermatomyositis (DM)2 and systemic sclerosis are the most common ACTDs which can be seen in calcinosis cutis. Calcinosis cutis in DM is frequently observed, especially in the juvenile-onset DM (JDM). However, calcinosis in juvenile-onset amyopathic dermatomyositis (amyopathic JDM) is rare.

CASE REPORT

A 6-year-old female presented with 0.5 to 2 cm-sized multiple hard subcutaneous masses on both knees for 3 years.
Fig. 1. (A) Skin manifestations of the patient. Subcutaneous nodules on both knees (black arrows, upper panels) and multiple erythematous scaly patches and plaques on bilateral knuckles, elbows, ankles and cheeks (middle and lower panels). (B) Skin manifestations of the mother. Erythematous scaly patches on the knuckles (left panel) and elbows (right panel).
The masses were painless and growing slowly. The patient also presented with multiple erythematous scaly patches and plaques on bilateral knuckles, elbows, ankles and cheeks from the first year of life (Fig. 1A). Her mother had similar skin lesions which were erythematous scaly patches on the knuckles, knees and elbows, since her childhood (Fig. 1B). Both patient and her mother had no history of muscle weakness, photosensitivity or arthralgia.

Skin biopsies were performed from two sites from the patient. When skin biopsy was performed from a left knee nodule, liquid chalky discharge which is called “milk of calcium” was observed. The biopsy results were consistent with calcinosis cutis which showed tumorous deposition with bursa-like structure lined by calcifying front (Fig. 2A). Another biopsy from erythematous scaly plaque on the right elbow showed focal hydropic degeneration of basal keratinocytes and lichenoid inflammatory cell infiltration (Fig. 2B). Skin biopsy was also performed from her mother. Histopathologic findings from erythematous patch on mother’s knee were mild basal vacuolar change and perivascular lymphohistiocytic cell infiltration (Fig. 2C). Laboratory findings showed normal range of serum phosphorus (4.5 mg/dl), calcium (9.3 mg/dl), 1,25-dihydroxy-vitamin D (10.8 ng/ml) and parathyroid hormone levels (11 pg/ml). The level of creatine kinase (CK) which is a muscle-specific enzyme was normal (62 IU/L), and myositis-specific antibody (Jo-1) was negative. Anti-nuclear antibody (ANA), anti-Smith antibody, anti-Ro/SSA antibody, anti-La/SSB antibody and anti-ribonucleoprotein antibody were negative. Mother also had normal serum P, Ca, 1,25-dihydroxy-vitamin D and CK levels and negative autoantibodies including ANA, Jo-1. Of note, both patient and mother were rheumatoid factor (RF) positive. To rule out possibility of nonphosphatemic familial tumoral calcinosis (NFTC) genetic analysis was performed for Sterile Alpha Motif Domain Containing 9 (SAMD9) mutation which is known as key mutation of NFTC, the result was negative.

Plain radiographs and magnetic resonance imaging (MRI) revealed multi-nodular extensive soft tissue calcification at the mainly anterior aspect of knee joints of the patient (Fig. 3). There was no evidence of muscle involvement in MRI. Electromyography and muscle biopsy were not performed.

Both patient and her mother were diagnosed with amyopathic JDM based on histopathology and characteristic inflammatory cutaneous manifestations with no clinical evidence of muscle weakness and no serum muscle enzyme abnormalities. Tumoral calcium deposits with “milk of calcium” observed in the patient was diagnosed as dystrophic calcinosis which can be rarely seen in amyopathic JDM.

The patient is being treated with oral acetazolamide (40 mg/kg/d) to manage calcinosis, and the mother is being
treated with oral hydroxychloroquine.

**DISCUSSION**

Amyopathic JDM is an uncommon variant of JDM and is easily under-recognized. A definition of amyopathic JDM is biopsy confirmed hallmark cutaneous features of DM with onset of under 18 years of age for at least 6 months without clinical or laboratory evidence of muscle disease. Classical inflammatory cutaneous manifestations of DM include Gottron’s papules, periorbital erythema, periungual telangiectasia, and symmetrical violaceous erythema overlying extensor arms and in a shawl-like distribution. No consensus has been made about the minimum condition of skin manifestations required to satisfy the definition of classical or hallmark cutaneous manifestations of DM. In our case, both the patient and her mother had inflammatory skin manifestation such as Gottron’s papule and symmetrical erythematous patch on extensor side of arms since their childhood. And they showed no symptom of muscle weakness and no abnormality of muscle-specific enzyme and myositis-specific antibody. Histopathologic findings of them showed basal layer hydropic changes which can be seen in DM. Autoantibodies including ANA were negative in the patient and mother except for RF. The results of positive RF in both patients strongly indicated an underlying ACTD. In a systematic review of 68 cases of amyopathic JDM, a positive ANA titer was present in about one-half of patients and no mention was made of RF. However, RF was also observed in patients of JDM as in a previous report.

Calcinosi s is a frequent complication of classic JDM, which occurs in more than one third of patients with JDM. In contrast, calcinosis in amyopathic JDM is rarely seen. Only 3 cases of 68 (4%) with amyopathic JDM in the systematic review reported calcinosis. Of note, all of these 3 cases evolved into classical DM. Plain radiographs are generally sufficient for identifying calcinosis, and MRI can help to see the relationship to the surrounding soft tissue.

The chief complaint of our patient was tumoral deposition of calcium, and she was initially diagnosed at our clinic although her skin manifestations started 5 years ago. Calcino sis can be observed as an initial complaint before diagnosis of JDM, and diagnosis of JDM can be delayed. Delayed treatment of JDM may be one of the risk factors of calcinosis, and vice versa. Although delayed treatment of JDM has been mentioned as one of the risk factors which cause calcinosis, early treatment with systemic steroid has not been shown to ensure prevention of calcinosis in a previous prospective study.

Calcinosi s associated with DM is dystrophic calcinosis which is characterized by normal calcium and phosphate levels in serum and can be categorized into five subtypes: (1) small and hard plaques or nodules just below the skin surface; (2) large tumorous deposition which often appear ‘popcorn-like’ on X-ray examination; (3) deposits in the intermuscular fascia with limitation of movement in the involved muscle group; (4) a severe form which resembles an exoskeleton; and (5) a mixed form of calcinosis. Tumoral calcium deposition in JDM can be shown in 20% of calcinosis in JDM, and when fluid of calcium is collected in pseudobursae, “milk of calcium” can be observed as in our case. Tumoral calcium deposition should be differentiated from primary tumoral calcinosis (TC), especially normophosphatemic type. TC is a rare disease with the deposition of calcified masses in cutaneous and subcutaneous tissues in peri-articular area. TC is divided into primary TC and secondary TC which is com-
bined with underlying calcifying disease such as chronic renal failure. Serum phosphate levels demarcate the two major subtypes of primary TC, hyperphosphatemic FTC and NFTC. NFTC is characterized by the absence of metabolic abnormalities and dystrophic calcnosis and NFTC initially manifests with a nonspecific erythematous rash during the first year of life. NFTC is considered to be exceedingly rare, with only six families of Jewish-Yemenite origin reported in literature. SAMD9 mutation was found in all six families and SAMD9 may play a role in ectopic calcification as an interferon-gamma responsive protein. However, our patient was negative for SAMD9 mutation, which suggests different pathomechanism in different ethnic groups.

Repetitive trauma, active inflammation, and calcium metabolism abnormality have been suggested as pathogenic factors of calcnosis in JDM. Dystrophic calcification in JDM can occur anywhere, but large tumorous depositions tend to occur in traumatic locations. Our patient who has large masses around left knee joint also had left patella fracture three years ago. Management of calcnosis is challenging, and it should be accompanied by avoidance of trauma. Medical treatment strategies can be divided into anti-inflammatory drugs such as intravenous immunoglobulin and drugs which affect calcium metabolism including diltiazem, aluminum hydroxide suspension, probenecid and colchicine. Although many treatment options have been suggested to control calcnosis in JDM, no therapy has proven to be effective. We tried carbonic anhydrase inhibitor acetazolamide which induces phosphaturia by proximal tubular renal acidosis. Acetazolamide may have a valuable synergistic effect in TC.

Surgical excision of localized calcium deposits may be successful, but generally excision is not recommended as a treatment of choice because of high risk of poor wound healing and possibility of recurrence and infection. Furthermore, even biopsy for TC is better avoided for fear of infection. In our case, cellulitis occurred at the site of biopsy on patient’s knee (Fig. 3B).

The present case is peculiar in that it is a rare case of TC in amyopathic JDM and that it manifested as an initial presentation of amyopathic JDM. Dermatologists should be aware that calcnosis could be an initial presentation of amyopathic JDM and patients with amyopathic JDM especially combined with calcnosis need to be monitored closely for development of myositis, evolving into classical DM.

REFERENCES

1. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosi cutis: part I. Diagnostic pathway. J Am Acad Dermatol 2011;65:1-12; quiz 13-14.
2. Balci DD, Celik E, Sarikaya G, Yenin JZ, Atik E. The coexistence of vulvar lichen sclerosis, ulcerated calcinosi cutis, and dermatomyositis: coincidence or immunological mechanism? Ann Dermatol 2011;23(Suppl 3):S375-S379.
3. Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosi cutis occurring in association with autoimmune connective tissue disease: the Mayo clinic experience with 78 patients, 1996-2009. Arch Dermatol 2012;148:455-462.
4. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol 2007;157:637-644.
5. Walling HW, Gerami P, Sontheimer RD. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management. Paediatr Drugs 2010;12:23-34.
6. Gowdie PJ, Allen RC, Kornberg AJ, Akikusa J. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 2013;16:561-567.
7. Samson C, Soulen RL, Gursel E. Milk of calcium fluid collections in juvenile dermatomyositis: MR characteristics. Pediatr Radiol 2000;30:28-29.
8. Jiang Y, Qi Y, Liu D, Wang S, Li L. A case of juvenile dermatomyositis with severe calcinosi and successful treatment with prednisone and diltiazem. Int J Dermatol 2011;50:74-77.
9. Mukamel M, Horev G, Mimouni M. New insight into calcinosi of juvenile dermatomyositis: a study of composition and treatment. J Pediatr 2001;138:763-766.
10. Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosi during diltiazem treatment in juvenile dermatomyositis. J Rheumatol 1996;23:2152-2155.
11. Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosi with juvenile dermatomyositis, and successful treatment with prednisone and diltiazem. Br J Dermatol 2001;144:894-897.
12. Shimizu M, Ueno K, Ishikawa S, Yokoyama T, Kasahara Y, Yachie A. Cutaneous calcinosi in juvenile dermatomyositis. J Pediatr 2013;163:921.
13. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosi in juvenile dermatomyositis. Curr Rheumatol Rep 2014;16:467.
14. De Castro TC, Guarniero R, Giacomini MF, Meneghin MB, Martins GB, Lotufo Sde A. "Milk of calcium": a rare presentation of calcinosi. Rev Bras Reumatol 2014;54:65-67.
15. Sprecher E. Familial tumoral calcinosi: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol 2010;130:652-660.
16. Hershkovitz D, Gross Y, Nahum S, Yehezkel S, Sarig O, Ulito J, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosi. J Invest Dermatol 2011;131:662-669.
17. Shimizu M, Ueno K, Ishikawa S, Kasahara Y, Yachie A. Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. Rheumatology (Oxford) 2014;53:766-767.
18. Peñate Y, Guillermo N, Melwani P, Martel R, Hernández-Machín B, Borrego L. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol 2009;60:1076-1077.
19. Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. Horm Res 2009;71:178-184.
20. Marie I, Ménard JF, Hachulla E, Chérin P, Benveniste O, Tiev K, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011;41:48-60.